---
title: "CLRB: Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296262059.md"
description: "Lead asset iopofosine | 131 demonstrated strong efficacy and safety in WM, advancing to Phase 3 with regulatory designations and a large addressable market. The pipeline includes promising candidates for TNBC and pancreatic cancer, supported by a robust financial position and experienced leadership.Original document: Cellectar Biosciences, Inc. [CLRB] Slides Release — Aug. 18 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-18T19:20:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296262059.md)
  - [en](https://longbridge.com/en/news/296262059.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296262059.md)
generator: "portal-rs"
---

# CLRB: Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials

Lead asset iopofosine | 131 demonstrated strong efficacy and safety in WM, advancing to Phase 3 with regulatory designations and a large addressable market. The pipeline includes promising candidates for TNBC and pancreatic cancer, supported by a robust financial position and experienced leadership.

Original document: Cellectar Biosciences, Inc. \[CLRB\] Slides Release — Aug. 18 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CLRB.US](https://longbridge.com/en/quote/CLRB.US.md)

## Related News & Research

- [CLRB: Strong clinical progress and financing position support upcoming NDA submission in WM](https://longbridge.com/en/news/295790594.md)
- [AI Was Supposed to Kill Wix. Google Just Gave It a Way to Fight Back.](https://longbridge.com/en/news/297433684.md)
- [05:00 ETNorroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC](https://longbridge.com/en/news/297758164.md)
- [The Bot Now Clicks Buy: Your AI Is About To Start Spending Your Money](https://longbridge.com/en/news/297424265.md)
- [Alpha Tau completes enrollment in 48-patient IMPACT pancreatic cancer Alpha DaRT pilot study](https://longbridge.com/en/news/297513505.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**